The behavioral effects of acute and chronic JL 13, a putative antipsychotic, in Cebus non-human primates

Daniel Casey, J. Bruhwyler, J. Delarge, J. Géczy, J. F. Liégeois

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Rationale: Neuroleptic or antipsychotic drugs are the mainstay of treating acute and chronic psychosis. However, their efficacy is offset by a wide array of side effects, especially extrapyramidal syndromes (EPS). In an attempt to develop novel antipsychotic agents, several animal models have been developed to characterize the profile of new chemical entities. Objective: To evaluate the behavioral characteristics of JL 13, a potentially unique antipsychotic agent, three separate studies across a wide dose range in Cebus monkeys were conducted and compared with two studies of oral and parenteral haloperidol. Methods: Twelve Cebus monkeys were tested with single i.m. doses of JL 13 (0.1-2.5 mg/kg), single p.o. doses (1.0-50.0 mg/kg), and 35 days of continuous p.o. (up to 25 mg/kg) treatments and were blindly evaluated. The same twelve monkeys were also tested with haloperidol i.m. (0.01-0.25 mg/kg) and nine of the monkeys also received haloperidol p.o. (0.1-5.0 mg/kg). Behaviors scored included sedation/arousal, locomotor activity, EPS of parkinsonism and dystonia, as well as reactivity. Results: JL 13 produced mild to moderate and dose-related increased sedation and decreased locomotor activity. Minimal decreases in eye blinking rates were also noted as a consequence of sedation. Mild dystonia and parkinsonian symptoms of slow movement developed at the highest dose tested of 50 mg/kg p.o. in only 6 of 12 monkeys. This is 50 times higher than oral doses of haloperidol that would be needed to produce similar EPS effects. Dose-related EPS of dystonia and bradykinesia occurred in relation to decreased locomotor activity and reactivity to stimuli with haloperidol i.m. and p.o., which are features characteristically seen with traditional neuroleptics. Conclusions: The behavioral effects of JL 13 in non-human primates suggest this compound is well tolerated and may have a favorable antipsychotic benefit/risk ratio in the clinic, especially if antipsychotic efficacy occurs at doses well below those that can cause EPS.

Original languageEnglish (US)
Pages (from-to)228-235
Number of pages8
JournalPsychopharmacology
Volume157
Issue number3
DOIs
StatePublished - 2001

Fingerprint

Cebus
Primates
Antipsychotic Agents
Haloperidol
Haplorhini
Dystonia
Locomotion
Blinking
Hypokinesia
Parkinsonian Disorders
5-(4-methylpiperazin-1-yl)-8-chloropyrido(2,3-b)(1,5)benzoxazepine fumarate
Arousal
Psychotic Disorders
Animal Models
Odds Ratio

Keywords

  • Clozapine
  • Dopamine
  • Extrapyramidal side effect
  • Haloperidol
  • JL 13
  • Non-human primate
  • Serotonin

ASJC Scopus subject areas

  • Pharmacology

Cite this

The behavioral effects of acute and chronic JL 13, a putative antipsychotic, in Cebus non-human primates. / Casey, Daniel; Bruhwyler, J.; Delarge, J.; Géczy, J.; Liégeois, J. F.

In: Psychopharmacology, Vol. 157, No. 3, 2001, p. 228-235.

Research output: Contribution to journalArticle

Casey, Daniel ; Bruhwyler, J. ; Delarge, J. ; Géczy, J. ; Liégeois, J. F. / The behavioral effects of acute and chronic JL 13, a putative antipsychotic, in Cebus non-human primates. In: Psychopharmacology. 2001 ; Vol. 157, No. 3. pp. 228-235.
@article{e617afdc83c84707b58c1a62838b42cf,
title = "The behavioral effects of acute and chronic JL 13, a putative antipsychotic, in Cebus non-human primates",
abstract = "Rationale: Neuroleptic or antipsychotic drugs are the mainstay of treating acute and chronic psychosis. However, their efficacy is offset by a wide array of side effects, especially extrapyramidal syndromes (EPS). In an attempt to develop novel antipsychotic agents, several animal models have been developed to characterize the profile of new chemical entities. Objective: To evaluate the behavioral characteristics of JL 13, a potentially unique antipsychotic agent, three separate studies across a wide dose range in Cebus monkeys were conducted and compared with two studies of oral and parenteral haloperidol. Methods: Twelve Cebus monkeys were tested with single i.m. doses of JL 13 (0.1-2.5 mg/kg), single p.o. doses (1.0-50.0 mg/kg), and 35 days of continuous p.o. (up to 25 mg/kg) treatments and were blindly evaluated. The same twelve monkeys were also tested with haloperidol i.m. (0.01-0.25 mg/kg) and nine of the monkeys also received haloperidol p.o. (0.1-5.0 mg/kg). Behaviors scored included sedation/arousal, locomotor activity, EPS of parkinsonism and dystonia, as well as reactivity. Results: JL 13 produced mild to moderate and dose-related increased sedation and decreased locomotor activity. Minimal decreases in eye blinking rates were also noted as a consequence of sedation. Mild dystonia and parkinsonian symptoms of slow movement developed at the highest dose tested of 50 mg/kg p.o. in only 6 of 12 monkeys. This is 50 times higher than oral doses of haloperidol that would be needed to produce similar EPS effects. Dose-related EPS of dystonia and bradykinesia occurred in relation to decreased locomotor activity and reactivity to stimuli with haloperidol i.m. and p.o., which are features characteristically seen with traditional neuroleptics. Conclusions: The behavioral effects of JL 13 in non-human primates suggest this compound is well tolerated and may have a favorable antipsychotic benefit/risk ratio in the clinic, especially if antipsychotic efficacy occurs at doses well below those that can cause EPS.",
keywords = "Clozapine, Dopamine, Extrapyramidal side effect, Haloperidol, JL 13, Non-human primate, Serotonin",
author = "Daniel Casey and J. Bruhwyler and J. Delarge and J. G{\'e}czy and Li{\'e}geois, {J. F.}",
year = "2001",
doi = "10.1007/s002130100808",
language = "English (US)",
volume = "157",
pages = "228--235",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - The behavioral effects of acute and chronic JL 13, a putative antipsychotic, in Cebus non-human primates

AU - Casey, Daniel

AU - Bruhwyler, J.

AU - Delarge, J.

AU - Géczy, J.

AU - Liégeois, J. F.

PY - 2001

Y1 - 2001

N2 - Rationale: Neuroleptic or antipsychotic drugs are the mainstay of treating acute and chronic psychosis. However, their efficacy is offset by a wide array of side effects, especially extrapyramidal syndromes (EPS). In an attempt to develop novel antipsychotic agents, several animal models have been developed to characterize the profile of new chemical entities. Objective: To evaluate the behavioral characteristics of JL 13, a potentially unique antipsychotic agent, three separate studies across a wide dose range in Cebus monkeys were conducted and compared with two studies of oral and parenteral haloperidol. Methods: Twelve Cebus monkeys were tested with single i.m. doses of JL 13 (0.1-2.5 mg/kg), single p.o. doses (1.0-50.0 mg/kg), and 35 days of continuous p.o. (up to 25 mg/kg) treatments and were blindly evaluated. The same twelve monkeys were also tested with haloperidol i.m. (0.01-0.25 mg/kg) and nine of the monkeys also received haloperidol p.o. (0.1-5.0 mg/kg). Behaviors scored included sedation/arousal, locomotor activity, EPS of parkinsonism and dystonia, as well as reactivity. Results: JL 13 produced mild to moderate and dose-related increased sedation and decreased locomotor activity. Minimal decreases in eye blinking rates were also noted as a consequence of sedation. Mild dystonia and parkinsonian symptoms of slow movement developed at the highest dose tested of 50 mg/kg p.o. in only 6 of 12 monkeys. This is 50 times higher than oral doses of haloperidol that would be needed to produce similar EPS effects. Dose-related EPS of dystonia and bradykinesia occurred in relation to decreased locomotor activity and reactivity to stimuli with haloperidol i.m. and p.o., which are features characteristically seen with traditional neuroleptics. Conclusions: The behavioral effects of JL 13 in non-human primates suggest this compound is well tolerated and may have a favorable antipsychotic benefit/risk ratio in the clinic, especially if antipsychotic efficacy occurs at doses well below those that can cause EPS.

AB - Rationale: Neuroleptic or antipsychotic drugs are the mainstay of treating acute and chronic psychosis. However, their efficacy is offset by a wide array of side effects, especially extrapyramidal syndromes (EPS). In an attempt to develop novel antipsychotic agents, several animal models have been developed to characterize the profile of new chemical entities. Objective: To evaluate the behavioral characteristics of JL 13, a potentially unique antipsychotic agent, three separate studies across a wide dose range in Cebus monkeys were conducted and compared with two studies of oral and parenteral haloperidol. Methods: Twelve Cebus monkeys were tested with single i.m. doses of JL 13 (0.1-2.5 mg/kg), single p.o. doses (1.0-50.0 mg/kg), and 35 days of continuous p.o. (up to 25 mg/kg) treatments and were blindly evaluated. The same twelve monkeys were also tested with haloperidol i.m. (0.01-0.25 mg/kg) and nine of the monkeys also received haloperidol p.o. (0.1-5.0 mg/kg). Behaviors scored included sedation/arousal, locomotor activity, EPS of parkinsonism and dystonia, as well as reactivity. Results: JL 13 produced mild to moderate and dose-related increased sedation and decreased locomotor activity. Minimal decreases in eye blinking rates were also noted as a consequence of sedation. Mild dystonia and parkinsonian symptoms of slow movement developed at the highest dose tested of 50 mg/kg p.o. in only 6 of 12 monkeys. This is 50 times higher than oral doses of haloperidol that would be needed to produce similar EPS effects. Dose-related EPS of dystonia and bradykinesia occurred in relation to decreased locomotor activity and reactivity to stimuli with haloperidol i.m. and p.o., which are features characteristically seen with traditional neuroleptics. Conclusions: The behavioral effects of JL 13 in non-human primates suggest this compound is well tolerated and may have a favorable antipsychotic benefit/risk ratio in the clinic, especially if antipsychotic efficacy occurs at doses well below those that can cause EPS.

KW - Clozapine

KW - Dopamine

KW - Extrapyramidal side effect

KW - Haloperidol

KW - JL 13

KW - Non-human primate

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=0034813515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034813515&partnerID=8YFLogxK

U2 - 10.1007/s002130100808

DO - 10.1007/s002130100808

M3 - Article

C2 - 11605077

AN - SCOPUS:0034813515

VL - 157

SP - 228

EP - 235

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 3

ER -